ArticleBMC women's health2026
Telemedicine follow-up improves early detection of ovarian dysfunction after uterine artery embolization: a retrospective cohort study.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveUterine artery embolization (UAE) for fibroids may cause ovarian dysfunction, particularly concerning for reproductive-aged women. This study evaluated whether a structured telemedicine follow-up protocol enhances timely identification of early-stage ovarian dysfunction compared to traditional outpatient care, thereby expanding the therapeutic intervention window.
methodsThis retrospective cohort study analyzed 232 women aged 18–40 who underwent UAE at Fujian Maternity and Child Health Hospital (December 2020–2023). Participants were assigned to WeChat telemedicine platform (n = 138) or traditional follow-up (n = 94). Primary outcome was early identification of ovarian dysfunction, defined as diminished ovarian reserve (AMH < 1.1 ng/ml, FSH 10-15 IU/L), or subclinical POI (FSH 15-25 IU/L). Secondary outcomes included hormone replacement therapy adherence and quality of life scores.
resultsTelemedicine significantly improved early detection of ovarian dysfunction (21% vs 3%, p < 0.001), particularly in women aged 28–36 (OR = 7.84, 95%CI: 1.05–58.44). Follow-up completion increased substantially (3.83 ± 0.60 vs 2.67 ± 1.04 visits, p < 0.001). Among patients with confirmed dysfunction, telemedicine achieved superior hormone therapy adherence (82.8% vs 27.3% good adherence, p < 0.001) and better quality of life scores at 3 months (MENQOL: 49.83 ± 10.82 vs 59.09 ± 15.30, p = 0.038).
conclusionTelemedicine follow-up after UAE significantly is significantly associated with early detection of ovarian dysfunction and treatment adherence. Integration of structured remote monitoring protocols into post-UAE care pathways may improve long-term reproductive health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.